Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$10.20
-14.0%
$10.63
$4.92
$28.60
$8.35M1.36565,339 shs612,033 shs
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$4.72
-2.5%
$7.43
$4.36
$68.70
$8.76M0.42117,034 shs84,512 shs
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2.57
-3.2%
$3.07
$1.27
$9.47
$8.51M1.6856,861 shs21,239 shs
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$0.09
-44.6%
$0.09
$0.09
$2.48
$2.45M0.942.28 million shs14.57 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-14.00%-25.71%-7.52%+66.67%+25.93%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-2.48%-7.27%-0.21%-41.88%-92.68%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-3.21%-10.31%-22.27%-18.31%-29.53%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00%0.00%0.00%-56.82%+9,409,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
1.9383 of 5 stars
3.83.00.00.00.60.00.6
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.6295 of 5 stars
3.25.00.00.00.01.71.3
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.60
Strong Buy$25.00145.10% Upside
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.33
Hold$375.007,844.92% Upside
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00
N/AN/AN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PTN, ARTL, CYCN, and CLRB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/8/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$20.00
6/11/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/6/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
5/14/2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A$5.31 per shareN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/A$8.98 per shareN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2M4.12N/AN/A$3.27 per share0.78
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
$350K6.99N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$9.83M-$17.94N/AN/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/13/2025 (Estimated)
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$3.06M-$1.16N/AN/AN/A-34.02%-30.68%8/6/2025 (Estimated)
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/A-$1.55N/AN/AN/AN/AN/AN/A

Latest PTN, ARTL, CYCN, and CLRB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$3.70N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$0.13N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$0.78-$4.32-$3.54-$0.72N/AN/A
5/13/2025Q1 2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$5.10-$3.90+$1.20-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
0.49
0.49
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/A
2.47
2.47
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
4.21
4.21
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
16.41%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
11.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
5700,000698,000Not Optionable
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
101.81 million1.72 millionOptionable
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
303.21 million2.11 millionNo Data
Palatin Technologies Inc stock logo
PTN
Palatin Technologies
3026.01 millionN/AN/A

Recent News About These Companies

PL9643 shows promise in dry eye disease treatment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$10.20 -1.66 (-14.00%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.44 +0.24 (+2.34%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Cellectar Biosciences stock logo

Cellectar Biosciences NASDAQ:CLRB

$4.72 -0.12 (-2.48%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.76 +0.04 (+0.74%)
As of 08/1/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cyclerion Therapeutics stock logo

Cyclerion Therapeutics NASDAQ:CYCN

$2.56 -0.09 (-3.21%)
Closing price 08/1/2025 03:49 PM Eastern
Extended Trading
$2.64 +0.08 (+3.12%)
As of 08/1/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Palatin Technologies stock logo

Palatin Technologies NYSE:PTN

$0.09 -0.08 (-44.65%)
As of 05/7/2025

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.